alvocidib (flavopiridol)

01/01/2001 - "In addition, the present results suggest that flavopiridol may be more effective against types of cancer that are highly dependent on genes with unstable mRNAs."
08/01/2006 - "Efficacy of flavopiridol in enhancing tumor response to radiation was determined by tumor growth delay assay using SEG-1 tumor xenografts generated in nude mice. "
07/15/2004 - "A fractional radiation dose of 6 Gy in combination with flavopiridol produced a 62.5% cure rate compared with 25% tumor cure for radiation alone. "
02/01/2004 - "We demonstrate efficacy of flavopiridol as a single modality treatment in delaying tumor growth in both animal models. "
12/01/2003 - "When gamma-irradiation was administered 7 h before flavopiridol, 42% of the tumor-bearing animals were rendered disease free, compared with no animals treated with either gamma-irradiation or flavopiridol alone. "

01/15/2007 - "Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia."
10/01/2013 - "Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic leukemia (CLL) patients. "
03/01/2012 - "We retrospectively reviewed outcomes of refractory chronic lymphocytic leukemia patients in two age categories (≥70 and <70 years) treated with single-agent flavopiridol, a drug active in genomically high-risk patients, during two trials. "
12/10/2009 - "Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease."
03/19/2009 - "We previously reported interim results of a phase 1 trial in patients with chronic lymphocytic leukemia (CLL) whereby flavopiridol was administered intravenously as a 30-minute bolus followed by 4-hour infusion. "

07/01/2014 - "A screen of seven compounds with anti-CDK9 activity applied to a panel of leukemia cell lines identified flavopiridol and the experimental inhibitor PC585 as superior in efficacy with inhibitory concentrations in the submicromolar range. "
03/24/2011 - "Our phase 1 trial "hybrid FLAM" in 55 adults with relapsed/refractory acute leukemias began at a total flavopiridol dose of 50 mg/m(2) per day 3 times (20-mg/m(2) bolus, 30-mg/m(2) infusion). "
07/01/2010 - "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias."
01/12/2016 - "Moreover, Flavopiridol (CDK9 inhibitor) could inhibit THP-1 cell (monocytic acute leukemia cell line) proliferation by targeting CDK9. "
12/01/2005 - "These findings warrant continuing development of flavopiridol at 50 mg/m2/d x 3 days in combination with cytotoxic and biological agents for acute leukemias."

10/01/2021 - "Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia."
11/01/2012 - "Both flavopiridol schedules produce comparably encouraging results in adults with poor-risk acute myelogenous leukemia. "
10/01/2023 - "A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia."
09/07/2023 - "Flavopiridol is synthetic flavone that was recently approved by the FDA for the treatment of acute myeloid leukemia. "
12/05/2017 - "Combined venetoclax and alvocidib in acute myeloid leukemia."

01/01/2021 - "We therefore investigated whether exploiting elevated c-Myc expression is effective in treating esophageal cancer with the CDK inhibitor flavopiridol. "
08/01/2006 - "Previous studies have shown that alvocidib could potentially treat esophageal cancer in vitro. "
01/01/2021 - "Esophageal cancer cells with elevated c-Myc expression were found preferentially more sensitive to induction of apoptosis by the CDK inhibition flavopiridol compared to esophageal cancer cells with lower c-Myc expression. "
01/01/2004 - "Flavopiridol as a radio-sensitizer for esophageal cancer cell lines."
11/01/1998 - "Although the precise mechanism of flavopiridol-mediated cytotoxicity has not been fully defined, this drug is an attractive agent for molecular intervention in esophageal cancers and their precursor lesions; further evaluation of flavopiridol in this clinical context is warranted."